PTRF Confers Melanoma-Acquired Drug Resistance Through the Upregulation of EGFR

Abstract

Melanoma is the most serious type of skin cancer. About half of all melanomas have activating BRAF mutations. Targeted therapy for malignant melanoma with BRAF inhibitor (BRAFi) or its combination with MEK inhibitor (MEKi) improves the clinical outcomes of patients, but resistance develops invariably. The underlying mechanisms remain incompletely understood. Here, we show that caveolae number is increased in both BRAFi and BRAFi + MEKi-resistant melanoma cells, and the expression of the critical caveolae component PTRF is significantly upregulated in drug-resistant melanoma cell lines and tumour tissues. Knockdown of PTRF in drug-resistant cells reduces proliferation with increased apoptosis, whereas ectopic expression of PTRF confers resistance on parental cells to BRAFi or BRAFi + MEKi. On the contrary, the knockdown of PTRF in parental cells reduces their ability to acquire drug resistance induced by BRAFi treatment. Interestingly, we find that the expression of EGFR is increased along with PTRF and caveolin-1 in drug-resistant cells and in PTRF transduced parental cells, whereas knockdown of PTRF results in down-regulation of EGFR expression and attenuates drug resistance of parental cells induced by PTRF expression. Together, these results suggest that PTRF contributes to therapy resistance through upregulating EGFR in melanoma cells.

Keywords

caveolae / drug resistance / EGFR / melanoma / PTRF

References

[1] G. E. Palade, “Fine Structure of Blood Capillaries,” Journal of Applied Physics 24 (1953): 1424.

[2] G. E. Palade and R. R. Bruns, “Structural Modulations of Plasmalemmal Vesicles,” Journal of Cell Biology 37 (1968): 633–649.

[3] R. G. Parton, “Caveolae: Structure, Function, and Relationship to Disease,” Annual Review of Cell and Developmental Biology 34 (2018): 111–136.

[4] N. Baker and R. S. Tuan, “The Less-Often-Traveled Surface of Stem Cells: Caveolin-1 and Caveolae in Stem Cells, Tissue Repair and Regeneration,” Stem Cell Research & Therapy 4 (2013): 90.

[5] R. G. Parton and M. A. del Pozo, “Caveolae as Plasma Membrane Sensors, Protectors and Organizers,” Nature Reviews. Molecular Cell Biology 14 (2013): 98–112.

[6] U. E. Martinez-Outschoorn, F. Sotgia, and M. P. Lisanti, “Caveolae and Signalling in Cancer,” Nature Reviews. Cancer 15 (2015): 225–237.

[7] T. M. Williams and M. P. Lisanti, “The Caveolin Proteins,” Genome Biology 5 (2004): 214.

[8] R. G. Parton, V. A. Tillu, and B. M. Collins, “Caveolae,” Current Biology 28 (2018): R402–R405.

[9] A. R. Busija, H. H. Patel, and P. A. Insel, “Caveolins and Cavins in the Trafficking, Maturation, and Degradation of Caveolae: Implications for Cell Physiology,” American Journal of Physiology. Cell Physiology 312 (2017): C459–C477.

[10] M. M. Hill, M. Bastiani, R. Luetterforst, et al., “PTRF-Cavin, a Conserved Cytoplasmic Protein Required for Caveola Formation and Function,” Cell 132 (2008): 113–124.

[11] L. Liu, D. Brown, M. McKee, et al., “Deletion of Cavin/PTRF Causes Global Loss of Caveolae, Dyslipidemia, and Glucose Intolerance,” Cell Metabolism 8 (2008): 310–317.

[12] P. I. Poulikakos, R. J. Sullivan, and R. Yaeger, “Molecular Pathways and Mechanisms of BRAF in Cancer Therapy,” Clinical Cancer Research 28 (2022): 4618–4628.

[13] R. B. Corcoran, H. Ebi, A. B. Turke, et al., “EGFR-Mediated Re-Activation of MAPK Signaling Contributes to Insensitivity of BRAF Mutant Colorectal Cancers to RAF Inhibition With Vemurafenib,” Cancer Discovery 2 (2012): 227–235.

[14] P. Lito, C. A. Pratilas, E. W. Joseph, et al., “Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas,” Cancer Cell 22 (2012): 668–682.

[15] C. C. Jiang, F. Lai, R. F. Thorne, et al., “MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720,” Clinical Cancer Research 17 (2011): 721–730.

[16] T. Inozume, T. Tsunoda, T. Morisaki, K. Harada, S. Shirasawa, and T. Kawamura, “Acquisition of Resistance to Vemurafenib Leads to Interleukin-10 Production Through an Aberrant Activation of Akt in a Melanoma Cell Line,” Journal of Dermatology 45 (2018): 1434–1439.

[17] J. Limberg, C. E. Egan, K. D. Gray, et al., “Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma,” Molecular Cancer Research 21 (2023): 397–410.

[18] J. Pastwinska, K. Karas, I. Karwaciak, and M. Ratajewski, “Targeting EGFR in Melanoma—The Sea of Possibilities to Overcome Drug Resistance,” Biochimica Et Biophysica Acta. Reviews on Cancer 1877 (2022): 188754.

[19] C. Mamot and C. Rochlitz, “Targeting the Epidermal Growth Factor Receptor (EGFR)—A New Therapeutic Option in Oncology?,” Swiss Medical Weekly 136 (2006): 4–12.

[20] C. Sun, L. Wang, S. Huang, et al., “Reversible and Adaptive Resistance to BRAF(V600E) Inhibition in Melanoma,” Nature 508 (2014): 118–122.

[21] E. Dratkiewicz, A. Simiczyjew, K. Pietraszek-Gremplewicz, J. Mazurkiewicz, and D. Nowak, “Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment,” International Journal of Molecular Sciences 21 (2019): 113.

[22] A. Gross, A. Niemetz-Rahn, A. Nonnenmacher, J. Tucholski, U. Keilholz, and A. Fusi, “Expression and Activity of EGFR in Human Cutaneous Melanoma Cell Lines and Influence of Vemurafenib on the EGFR Pathway,” Targeted Oncology 10 (2015): 77–84.

[23] Z. Ji, Y. Erin Chen, R. Kumar, et al., “MITF Modulates Therapeutic Resistance Through EGFR Signaling,” Journal of Investigative Dermatology 135 (2015): 1863–1872.

[24] R. G. Parton, K. A. McMahon, and Y. Wu, “Caveolae: Formation, Dynamics, and Function,” Current Opinion in Cell Biology 65 (2020): 8–16.

[25] S. M. Shaffer, M. C. Dunagin, S. R. Torborg, et al., “Rare Cell Variability and Drug-Induced Reprogramming as a Mode of Cancer Drug Resistance,” Nature 546 (2017): 431–435.

[26] A. Prahallad, C. Sun, S. Huang, et al., “Unresponsiveness of Colon Cancer to BRAF(V600E) Inhibition Through Feedback Activation of EGFR,” Nature 483 (2012): 100–103.

[27] M. P. Lisanti, P. E. Scherer, J. Vidugiriene, et al., “Characterization of Caveolin-Rich Membrane Domains Isolated From an Endothelial-Rich Source: Implications for Human Disease,” Journal of Cell Biology 126 (1994): 111–126.

[28] H. Ju, V. J. Venema, H. Liang, M. B. Harris, R. Zou, and R. C. Venema, “Bradykinin Activates the Janus-Activated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) Pathway in Vascular Endothelial Cells: Localization of JAK/STAT Signalling Proteins in Plasmalemmal Caveolae,” Biochemical Journal 351 (2000): 257–264.

[29] W. M. Krajewska and I. Maslowska, “Caveolins: Structure and Function in Signal Transduction,” Cellular & Molecular Biology Letters 9 (2004): 195–220.

[30] E. Yang, L. Wang, W. Jin, et al., “PTRF/Cavin-1 Enhances Chemo-Resistance and Promotes Temozolomide Efflux Through Extracellular Vesicles in Glioblastoma,” Theranostics 12 (2022): 4330–4347.

[31] J. S. Yi, D. G. Mun, H. Lee, et al., “PTRF/Cavin-1 Is Essential for Multidrug Resistance in Cancer Cells,” Journal of Proteome Research 12 (2013): 605–614.

[32] S. Tsai, C. Balch, and J. Lange, “Epidemiology and Treatment of Melanoma in Elderly Patients,” Nature Reviews. Clinical Oncology 7 (2010): 148–152.

[33] L. Bai, X. Deng, J. Li, et al., “Regulation of Cellular Senescence by the Essential Caveolar Component PTRF/Cavin-1,” Cell Research 21 (2011): 1088–1101.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.